Suppr超能文献

[特非那定单剂量给药:作为一项双盲研究,与标准治疗方法比较,用于过敏性鼻炎患者]

[Administration of terfenadine in a single dose: comparison to standard treatment, as a double blind study, in patients presenting with allergic rhinitis].

作者信息

Hugonot L, Hugonot R, Kurzeja A, Gastpar H, Rauch-Riedelsheimer B, Beaumont D, Köhler M, Henauer S

机构信息

C.H.R., Grenoble, France.

出版信息

Allerg Immunol (Paris). 1988 Dec;20(10):373-6.

PMID:3145752
Abstract

This double-blind, randomized multicentre study was designed to compare efficacy and tolerability of 120 mg terfenadine taken once daily (in the morning) with the established regimen of 60 mg terfenadine taken twice daily in the treatment of seasonal rhinitis. Two comparable groups, a total of 191 hay fever patients, were treated for 1 week. Symptom severity was assessed by the investigators before and at the end of the treatment (visual analogue scale), and daily by the patient (four-point rating scale). All symptoms improved to a similar degree in both groups. Differences between the two groups were not statistically significant, except for nasal symptoms in three cases as assessed by the visual analogue scale in one centre (better relief in the group given 120 mg terfenadine once daily). Tolerability was good and similar in both groups. The data presented show that in the treatment of hay fever 120 mg terfenadine given once daily is an effective, convenient and well tolerated alternative to the regimen of 60 mg terfenadine given twice daily.

摘要

这项双盲、随机多中心研究旨在比较每日清晨服用一次120毫克特非那定与既定的每日两次服用60毫克特非那定方案治疗季节性鼻炎的疗效和耐受性。两个可比组,共191名花粉症患者,接受了为期1周的治疗。研究者在治疗前和治疗结束时(视觉模拟评分)对症状严重程度进行评估,患者每天(四分制评分量表)进行评估。两组中所有症状均有相似程度的改善。两组之间的差异无统计学意义,但在一个中心用视觉模拟评分评估的三例鼻症状除外(每日服用一次120毫克特非那定的组缓解更好)。两组的耐受性均良好且相似。所呈现的数据表明,在治疗花粉症方面,每日服用一次120毫克特非那定是每日两次服用60毫克特非那定方案的一种有效、方便且耐受性良好的替代方案。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验